Eisai Co Ltd (OTCPK:ESAIY)
$ 11.15 0.157 (1.43%) Market Cap: 12.79 Bil Enterprise Value: 12.18 Bil PE Ratio: 37.17 PB Ratio: 2.45 GF Score: 59/100

Eisai Co Ltd Clarity AD Study Briefing Transcript

Nov 30, 2022 / 12:50AM GMT
Release Date Price: $70.1 (+8.26%)
Takeshi Iwatsubo

Good afternoon, everyone. I welcome to the symposium on Clarity AD, a Phase III placebo-controlled, double-blind, parallel-group, 18 months study evaluating lecanemab in early Alzheimer's disease. I'm Takeshi Iwatsubo from the University of Tokyo. I'm honored and very thrilled to chair this historic session in Alzheimer's research on therapeutics.

Many of you may well remember that on September 27 of this year, the top line results of Clarity AD as a first large completed a positive Phase III trial of disease modifying therapy of AD was announced, which represent a monumental event for patients and their families living with Alzheimer's disease and all scientists in this field, Eisai based in Koishikawa, Tokyo, and then headed by Mr. Haruo Naito, who is also here today, has been at the forefront of Alzheimer's Research over the past 4 decades from developing a symptomatic breakthrough treatment in the 1980s and '90s to the current industry-leading antibody development. The approach rose naturally from the human health care mission.

At this present session, 5 distinguished

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot